永勝醫療(01612.HK)全年淨利飆升17.8倍至2.2億港元 末期息11港仙
格隆匯 3 月 23日丨永勝醫療(01612.HK)發佈截至2020年12月31日止年度的全年業績公吿,2019冠狀病毒病疫情加速永勝醫療轉型為呼吸領域的全球主要醫療技術供應商的步伐。2020年的財務表現創出歷史新高,收入增加130.1%至11.554億港元,其中呼吸產品分部的收入增加285.6%至8.19億港元;毛利增加205.1%至4.942億港元;整體毛利率上升10.5個百分點至42.8%;公司擁有人應占溢利飆升17.8倍至2.169億港元;淨利潤率上升18.8個百分點至21.4%;每股基本盈利33.84港仙;擬派2020年末期股息為每股11.0港仙。
公吿表示,總收入按年增長130.1%,該增長反映了2019冠狀病毒病疫情、新產品推出以及成功拓展新市場而致使集團的呼吸類器械和耗材的市場需求強勁。地區市場方面,集團的收入貢獻日趨多元化。全球兩大醫療器械市場美國及中國分別佔集團2020年總收入的46.6%(2019年:63.6%)及17.5%(2019年:13.2%)。銷往印度、沙特阿拉伯及以色列的呼吸產品的收入亦有顯著增長,分別為2,265.2%、20,354.7%及651.1%。日本市場表現依然強勁,增長速度高於過往年度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.